Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: June 1, 2026 · This page is informational and does not constitute medical advice.
SURMOUNT-3 (Nature Medicine 2023) added tirzepatide to an intensive lifestyle intervention that already produced 6.9% weight loss. Combined intervention produced 26.6% total weight loss — the largest in any GLP-1 trial.
Clinical reference4 peer-reviewed sources
Editorial summary
SURMOUNT-3, published in Nature Medicine in 2023, used a sequential design to test tirzepatide in patients who had first completed a 12-week intensive lifestyle intervention. Of 806 enrolled adults, 579 lost ≥5% during the lifestyle phase and were randomized to tirzepatide (titrated to 10 or 15 mg) or placebo for 72 additional weeks. The tirzepatide group achieved 21.1% additional weight loss from post-lifestyle baseline, for cumulative weight loss of ~26.6% from initial baseline — the largest in any published GLP-1 RA trial¹.
Trial design and sequential approach
SURMOUNT-3 (Wadden et al., Nat Med 2023) used a two-phase sequential design unique among the SURMOUNT and STEP programs¹. Phase 1 (weeks 1-12): all 806 enrolled with BMI ≥30 or ≥27 with comorbidity received intensive lifestyle intervention. Phase 2 (weeks 13-84): the 579 participants who lost ≥5% during Phase 1 were randomized 1:1 to once-weekly tirzepatide titrated to maximum tolerated (10 or 15 mg) or placebo, both with continued lifestyle. Primary endpoint: % weight change from week 12 to week 84.
Phase 1: lifestyle alone
During the 12-week intensive lifestyle, mean weight loss was 6.9%. The 579 participants achieving ≥5% loss represented 71.8% of enrolled — a substantially higher proportion than typical in less intensive programs. Mean weight loss in this responder cohort at week 12: 7.6%.
Phase 2: tirzepatide vs placebo
From week 12 to week 84, tirzepatide lost an additional 21.1%, while placebo regained 3.3% — treatment difference -24.4 percentage points (95% CI -26.5 to -22.4; P<0.001)¹.
Cumulatively from original baseline to week 84, tirzepatide achieved mean total weight loss of ~26.6%. This is the largest weight loss reported in any published GLP-1 RA trial through 2026. The 24.4 percentage-point treatment difference also represents the largest randomized contrast in the obesity pharmacotherapy literature.
Why the larger effect size
Two factors likely contributed to the larger effect vs SURMOUNT-1 (22.5% at 15 mg). First, lifestyle pre-selection enriched for participants who could lose weight, biasing the cohort toward responders. Second, the intensive lifestyle co-intervention during Phase 2 was more rigorous than in SURMOUNT-1.
These considerations apply to practice: patients who can engage with structured behavioral support concurrently with pharmacotherapy may achieve substantially better outcomes than those receiving medication alone with minimal lifestyle reinforcement.
Adverse events
GI events dominated the adverse event profile. Nausea, diarrhea, constipation, vomiting most common, predominantly during dose escalation, mostly mild-moderate¹. Discontinuation due to adverse events ~6% in tirzepatide vs ~2% in placebo. Cholelithiasis occurred in 5.0% of tirzepatide vs 1.4% of placebo, consistent with SURMOUNT-1. No new safety signals.
$99 on 6 months · $105 on 3 months · $109 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded semaglutide is not FDA-approved and is not Wegovy or Ozempic. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
$119 on 6 months · $125 on 3 months · $129 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded tirzepatide is not FDA-approved and is not Zepbound or Mounjaro. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
SURMOUNT-3, combining tirzepatide with intensive lifestyle in selected lifestyle responders: ~26.6% mean weight loss at 84 weeks — the largest in any published GLP-1 RA trial.
Should I do intensive lifestyle before starting tirzepatide?
Sequential or combined intensive behavioral therapy with pharmacotherapy produces the strongest weight loss in randomized trials. The sequence matters less than ensuring both components are active concurrently.
SURMOUNT-3 vs SURMOUNT-1?
SURMOUNT-1 used standard lifestyle and showed 22.5% at 15 mg over 72 weeks. SURMOUNT-3 added intensive lifestyle and pre-selected responders, producing 26.6% over 84 weeks.
Was the lifestyle phase necessary?
Lifestyle pre-selected responders and provided ongoing behavioral support. The design cannot fully separate these effects from marginal tirzepatide benefit, but the combined approach produced the largest effect.
26% weight loss realistic in typical practice?
Achieving 26% requires intensive multidisciplinary support exceeding typical clinical settings. Most patients in standard practice achieve closer to SURMOUNT-1's 20-22% on 15 mg. SURMOUNT-3 represents an upper bound with optimal infrastructure.
References
Wadden TA, Chao AM, Machineni S, et al.Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: SURMOUNT-3 phase 3 trial.Nat Med. 2023;29(11):2909-2918.PMID: 37804337
Jastreboff AM, Aronne LJ, Ahmad NN, et al.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).N Engl J Med. 2022;387(3):205-216.PMID: 35658024
Aronne LJ, Sattar N, Horn DB, et al.Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4.JAMA. 2024;331(1):38-48.PMID: 38078870
Wadden TA, Bailey TS, Billings LK, et al.Effect of Subcutaneous Semaglutide vs Placebo as Adjunct to Intensive Behavioral Therapy: STEP 3.JAMA. 2021;325(14):1403-1413.PMID: 33724399
Citations are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed. FDA links resolve to fda.gov. All citations were last verified 2026-05-11.